glp-1 receptor antagonist Structure-Based Discovery of Orthosteric Non-Peptide GLP-1R Agonists via Integrated Virtual Screening and Molecular Dynamics How GLP-1 Receptor Agonists Evolved

One of the promising tools in our weight loss arsenal is semaglutide, a medication known for its remarkable ability to aid weight loss by regulating appetite

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

1 Depending on the specific molecules half-life, GLP-1 medications can also have a short-release or extended-release action, determining how long their effects last in the body

SURMOUNT-1 enrolled 2,539 adults with a mean baseline BMI of 38.0, and 94.5% of participants had a BMI of 30 or higher

Also available in 20mg, 30mg, and 40mg vials

The reported results are promising: Over 80% relative bioavailability Around 160 higher bioavailability vs oral tablets Sustained drug levels for ~1 week (once-weekly dosing potential) Additionally, the microneedle patches are stable at room temperature, eliminating the need for cold storage, unlike semaglutide injections